Humanigen Inc (HGENQ)

[cowtown jay]

I mentioned using lenz with some of the vaccines that the government has shelved, because I want to see a government stockpile order for lenz, and hopefully benefit by Defense Procurement Orders for lenz, if the company needs that.

But, I have always preferred Novavax. such as I said here:

"Secondly, I have always favored the Novavax (synthetic covid) virus traditional compound, versus the m-RNA Pfizer and Moderna vaccines. If we can't get US authorization for the early use of lenz, based on inflammation and CRP levels, especially for people like me who are in high risk of infection and disease progression, then I would like to take the Novavax vaccine, along with lenz, in much the same way we are using lenz as a prophylactic for CAR-T toxicities."

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169054579&txt2find=novavax

Using the Novavax vaccine as I described, seems to be right in-line with what the company is pursuing with the patent that was published on Nov 17th, although they don't mention Novavax.

But...

The latest Humanigen patent that was just published, was actually filed in May of 2021.

May of 2021 was also the initial target date for Novavax to file an EUA application, although management did not make the filing as planned. NVAX was awarded an EUA in July of this year.

https://www.yahoo.com/finance/news/novavax-nvax-stock-nosedives-88-173005622.html

I have a pro-NVAX bias. I like the traditional compounding of their vaccine, vs mRNA. I like how their CEO put US authorization at the end of the line, and focused on foreign approvals first. I like that, like us, this is the first product they have brought to market. And I think they would make an excellent partner for us in which both companies would have significant benefit.

With that said, I hope the second drug compound mentioned in our latest patent to be used with lenz, will include the NVAX vaccine.

"METHODS FOR TREATING CORONAVIRUS INFECTION AND RESULTING INFLAMMATION-INDUCED LUNG INJURY
Publication number: 20220363746
Abstract: The present invention provides methods for treating a subject infected with 2019 coronavirus (SARS-CoV-2) comprising administering to the subject a therapeutically effective amount of a GM-CSF antagonist or a therapeutically effective amount of a GM-CSF antagonist and a second drug, including an anti-viral agent, an anti-SARS-CoV-2 vaccine, and serum containing human polyclonal antibodies to SARS-CoV-2.
Type: Application
Filed: May 3, 2021
Publication date: November 17, 2022
Applicant: HUMANIGEN, INC.
Inventors: Cameron DURRANT, Dale CHAPPELL"

https://patents.justia.com/search?q=humanigen